S100A9 and myelodysplastic syndrome: This is in line with findings showing that S100A9-mediated NLPR3 inflammasome activation is associated with pyroptosis in bone marrow of MDS patients, suggesting that this mechanism may account for a number of clinical features of MDS17–19.